• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Direct comparison of neoadjuvant and adjuvant chemotherapy and radiotherapy for survival outcomes from resectable gastric cancer

byMeagan WidermanandMichael Pratte
December 15, 2021
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

1. Out of the therapies that were associated with longer overall survival versus no perioperative therapy, chemotherapy with unknown timing was associated with the longest overall survival of 53.9 months.

2. Neoadjuvant chemoradiation was associated with superior decreases in pathologic complete response than neoadjuvant chemotherapy and chemotherapy with unknown timing. Neoadjuvant chemotherapy was associated with decreased positive margins compared to adjuvant chemotherapy and neoadjuvant chemotherapy with adjuvant radiation.

Evidence Rating Level: 2 (Good)

Study Rundown: Overall survival (OS) from resectable gastric cancer (RGC) is improved with perioperative chemotherapy versus surgery alone, adjuvant chemotherapy versus surgery alone, and adjuvant chemoradiotherapy versus surgery alone. However, perioperative chemotherapy, adjuvant chemotherapy, and adjuvant chemoradiotherapy have never been directly compared. This study attempts to identify the optimal treatment of RGC based on OS, pathologic complete response (pCR), and surgical margin status (SMS). The OS, pCR, and SMS of RGC patients from the National Cancer Database (NCDB) were compared by the patient’s treatment. Specifically, patients were classified as receiving only neoadjuvant chemoradiation (nCRT; n = 85), neoadjuvant chemotherapy (nCT; n = 641), adjuvant chemotherapy (aCT; n = 353), adjuvant chemoradiation (aCRT; n = 658), neoadjuvant chemotherapy and adjuvant radiation (nCTaRT; n = 112), chemotherapy with timing unknown (CTTU; n = 540), chemoradiation therapy with timing unknown (CRTTU; n = 51), radiation therapy with timing unknown (RTTU; n = 23), and no perioperative therapy (NT; n = 601). Treatment with nCRT, nCT, RTTU compared to NT was associated with an increased odds of pCR, but nCRT was superior to nCT and CTTU. An increase in the odds of positive SMS was associated with aCT and nCTaRT compared to NT and compared to nCT. Baseline sociodemographic, clinical stage, and pathology were not associated with OS. Superior OS was however associated with treatment with nCRT, CTTU, aCT, aCRT, nCT, and nCTaRT compared to NT. The treatment with the longest OS (53.9 months) and percentage of patients surviving 2-years (65.6%) was CTTU. CTTU was superior to nCT, nCRT, and aCRT on pairwise analysis. RTTU had inferior OS (4.2 months) compared to NT (12.3 months). Since selection for the treatment was based on patient factors like age, fitness, and tumour characteristics, there is a high risk that the more fit patients who would always have had the best OS are selected for more aggressive treatment; thus, no causative information can be drawn from this retrospective cohort study. Additionally, the sample size is limited when the cohort is so divided into 9 different treatment pathways. Finally, this study excluded non-surgical candidates, which would include those who progressed after starting neoadjuvant therapy, introducing a risk of overestimating the effects of treatment.

Click to read the study in JAMA Network Open

Relevant Reading: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

In-Depth [retrospective cohort]: Gastric cancer patients with adenocarcinoma histology of stage cT2-T4b, any N, or M0 who underwent surgical resection were eligible. OS, pCR, and SMS were collected from the National Cancer Database (NCDB) and compared by patient treatment group on multivariate and pairwise analysis. 3064 patients (mean age = 68, 57.6% male, 20.7% Black, 48.9% White, 54.15% treated at an academic facility) with RGC were included in this analysis. Most patients included were stage 2 (50.2%), T3 (48.7%), and N0 (63.1%). Increased odds of pCR was associated with tumour stage (T2 vs T4: odds ratio [OR] = 3.70, 95% CI = 1.16-11.80, P = 0.03), positive nodal involvement (OR = 2.03, 95% CI = 1.05-3.92; P = 0.04), and nCRT (OR = 59.55, 95% CI = 10.63-333.56, P < 0.001), nCT (OR = 14.60, 95%CI = 2.81-75.73, P = 0.001), RTTU (OR = 29.94, 95% CI = 2.92-307.01, P = 0.004) treatment group compared to NT treatment group on multivariate analysis. nCRT was superiorly associated with pCR compared with nCT (OR = 4.08, 95%CI = 1.92-8.69; P = 0.005) and CTTU (OR = 30.78, 95% CI = 7.56-125.30, P < 0.001). Decreased odds of positive SMS was associated with earlier tumor stage (T2 vs T4: OR = 0.51, 95% CI = 0.38-0.70, P < .001), node negativity (OR = 1.27, 95% CI = 1.04-1.56, P = 0.02). There was an association between increased positive SMS and later clinical stage (Stage 3 vs 1: OR = 1.81, 95% CI = 1.27-2.58, P = 0.001), and higher grade (Grade 3 vs 1: OR = 6.20, 95% CI = 2.02-19.02, P = 0.001) on multivariate analysis. Increased odds of positive SMS, compared to NT and nCT, was associated with aCT (vs NT: OR = 1.46, 95% CI = 1.03-2.05, P = 0.032; vs nCT: OR = 1.76, 95% CI = 1.25-2.48, P = 0.047) and nCTaRT (vs NT: OR = 2.04, 95% CI = 1.27-3.26, P = 0.003; vs nCT: OR = 2.46, 95% CI = 1.54-3.91, P = 0.006). Improvement in OS was associated with nCRT (hazard ratio [HR] = 0.48, 95% CI = 0.35-0.66, P < 0.001), CTTU (HR = 0.41, 95% CI = 0.35-0.48, P < 0.001), aCT (HR = 0.52, 95% CI = 0.43-0.62, P < .001), aCRT (HR = 0.55, 95% CI = 0.48-63, P < 0.001), nCT (HR = 0.61, 95% CI = 0.53-0.71, P < 0.001), and nCTaRT (HR = 0.67, 95% CI = 0.52-0.87, P = 0.003) compared with NT. CTTU was associated with the longest OS (53.9 months, 95% CI = 44.5-61.0 months), highest 2-year OS rate (65.6%, 95%CI = 61.3%-69.5%) and was superior to nCT (HR = 0.66, 95% CI = 0.56-0.78, P < 0.001), nCRT (HR = 0.61, 95% CI = 0.46-0.79, P = 0.007), and aCRT (HR = 0.74, 95% CI = 0.63-0.87, P = 0.009). RTTU had the shortest OS (4.2 months, 95% CI = 2.5-18.6 months), which was inferior to NT (12.3 months, 95% CI = 10.4-14.6 months).

RELATED REPORTS

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

Adjuvant chemotherapy associated with an improved overall survival for patients with locally advanced gastric cancer

S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: gastric cancer
Previous Post

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization

Next Post

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

RelatedReports

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

April 13, 2022
Quick Take: Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Tria
Chronic Disease

Adjuvant chemotherapy associated with an improved overall survival for patients with locally advanced gastric cancer

April 11, 2022
Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer
Chronic Disease

S-1 plus oxaliplatin noninferior to fluorouracil, leucovorin, and oxaliplatin in perioperative chemotherapy for locally advanced gastric cancer: FOCUS trial

March 1, 2022
Equivalent efficacy of Paclitaxel or Irinotecan for advanced gastric cancer
Gastroenterology

Postoperative chemotherapy in chemosensitive patients undergoing surgical treatment of gastric cancer may prolong survival

November 25, 2021
Next Post
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

Adolescents’ muscle strength associated with lower cardiometabolic risk

Wellness Check: Exercise

Social integration may reduce suicide risk in male health professionals

High levels of stress decreased amongst Korean youth during the COVID-19 pandemic

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.